Conti R, Parenti F
Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S600-5. doi: 10.1093/clinids/5.supplement_3.s600.
Rifampin has a broad antibacterial spectrum. At high concentrations it also is active in vitro against protozoa, i.e., different species of Leishmania. Rifampin has been used against bacterial and occasionally protozoal infections. Addition of rifampin to a tetracycline regimen was found to reduce the number of relapses in patients with acute and chronic brucellosis. In a few cases of meningitis due to Flavobacterium meningosepticum, which failed to respond to other drugs, patients were treated successfully with rifampin administered either orally or intravenously. Rifampin at doses of greater than or equal to 600 mg daily has been administered to patients with cutaneous leishmaniasis. Healing of skin lesions was observed in the majority of treated patients. Controlled studies are needed to assess the usefulness of rifampin in this disease.
利福平具有广泛的抗菌谱。在高浓度时，它在体外对原生动物也有活性，即不同种类的利什曼原虫。利福平已被用于治疗细菌感染，偶尔也用于治疗原生动物感染。在四环素治疗方案中添加利福平，可减少急性和慢性布鲁氏菌病患者的复发次数。在少数由脑膜炎败血黄杆菌引起的、对其他药物无反应的脑膜炎病例中，口服或静脉注射利福平成功治愈了患者。对于皮肤利什曼病患者，已给予每日剂量大于或等于600毫克的利福平。大多数接受治疗的患者皮肤损伤均有愈合。需要进行对照研究来评估利福平在这种疾病中的效用。
